drugset / Trial / NCT00712855
A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of escalating doses of mapatumumab in combination with sorafenib in subjects with advanced Hepatocellular Carcinoma who are positive for hepatitis B surface antigen or hepatitis C antibody.
Timeline
- Start
- 2008-06
- Primary completion
- 2011-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mapatumumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Mapatumumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Mapatumumab | Monoclonal antibody | 30 mg/kg | Intravenous |
| Background | Sorafenib | Small molecule | 400 mg | Oral |